NCT02155322View on ClinicalTrials.gov

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 19, 2014

Primary Completion Date

March 21, 2016

Study Completion Date

March 21, 2016

Conditions
Melanoma
Interventions
BIOLOGICAL

Pegylated Interferon Alfa-2b

6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks

BIOLOGICAL

Pegylated Interferon Alfa-2b

3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02155322 - A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) | Biotech Hunter | Biotech Hunter